This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albers, G. W. Articles by Choi, D. W. Search for Related Content PubMed PubMed Citation Articles by Albers, G. W. Articles by Choi, D. W.

Stroke, Vol 22, 1075-1077, Copyright © 1991 by American Heart Association

ARTICLES

Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia

GW Albers, RE Saenz, JA Moses Jr and DW Choi
Department of Neurology and Neurological Sciences, Stanford University Medical Center, Calif.

Experimental ischemia models have shown the antitussive dextromethorphan to be an N-methyl-D-aspartate antagonist with neuroprotective properties. We treated 10 patients with a history of recent stroke or transient ischemic attack with oral dextromethorphan (60 mg q.i.d.) for 3 weeks in a placebo-controlled, double-blind, crossover tolerance study. We documented no clinical evidence of toxicity attributable to dextromethorphan in this preliminary study.

This article has been cited by other articles:

				H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]

				A. A. Weinbroum, V. Rudick, G. Paret, and R. Ben-Abraham The role of dextromethorphan in pain control Can J Anesth, June 1, 2000; 47(6): 585 - 596. [Abstract] [Full Text] [PDF]

				W. Danysz and C. G. Parsons Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664. [Abstract] [Full Text] [PDF]

				P. J. Dorman and P. A.G. Sandercock Considerations in the Design of Clinical Trials of Neuroprotective Therapy in Acute Stroke Stroke, September 1, 1996; 27(9): 1507 - 1515. [Full Text]